"Financial Toxicity in Cancer Care, Explained"
Financial toxicity is the term cancer care uses for the harm a patient experiences because of the cost of their treatment. The National Cancer Institute's Dictionary of Cancer Terms defines it as problems a patient has related to the cost of medical care, and uses financial toxicity and financial distress interchangeably. NCI's fuller PDQ summary on financial toxicity and cancer treatment is where the mechanisms are laid out, including out-of-pocket costs, lost income, and the effect on whether people delay or skip care. The word "toxicity" is deliberate. Oncology already tracks, grades, and manages the toxic effects of treatment, and the term places cost in that same category: a treatment-related harm that clinicians should recognize, ask about, and respond to rather than treat as somebody else's department.
This article explains the term, how it is measured, and who in a cancer program addresses it. It is not medical or financial advice. Anyone facing cost pressure during treatment should speak with their cancer center's financial counselor or an oncology social worker.
Where the Term Comes From
Financial toxicity entered common use in oncology literature and practice over the last decade and a half, as newer cancer therapies, higher cost sharing, and longer survival extended the period over which patients pay. The National Cancer Institute's definition is the one most commonly cited because it is short, plain, and authoritative, and because NCI's dictionary entries function as the reference definition for cancer terminology generally.
The concept has two halves that are easy to conflate. There is the objective financial burden, meaning what a household actually pays and loses. And there is the subjective experience of that burden, meaning distress, worry, and the behavioral consequences such as skipping doses, delaying scans, or not filling prescriptions. Both are part of financial toxicity, and instruments that measure it generally try to capture the subjective side, because that is what predicts behavior and what a care team can respond to.
What Actually Drives It
Financial toxicity is not one thing. It accumulates from several independent mechanisms, which is why it can affect insured patients and why a single intervention rarely resolves it.
- Direct out-of-pocket medical costs. Deductibles, coinsurance on infused drugs, specialty pharmacy copays, imaging, and facility fees. Coinsurance is particularly consequential in oncology because it is a percentage of a high price rather than a flat amount.
- Underinsurance. Having coverage that leaves a large share of cost with the patient. Plan design, not lack of a plan, is often the driver.
- Lost income. Reduced hours or leaving work during treatment, for the patient and often for a family caregiver as well. This side is invisible to the billing system entirely.
- Indirect and nonmedical costs. Transportation, parking, lodging near a treatment center, childcare, and dietary changes. These are rarely captured anywhere in the record.
- Duration. Cancer treatment and survivorship extend across benefit years, so deductibles reset and costs recur.
Because the mechanisms differ, so do the remedies. A copay foundation grant addresses drug cost sharing and does nothing about lost wages. A transportation benefit addresses access and does nothing about a deductible. Programs that treat financial toxicity as a single problem with a single referral tend to under-serve it.
How It Is Measured: The COST Measure
The most widely used instrument is the COmprehensive Score for financial Toxicity, known as COST, developed by researchers at the University of Chicago and published as part of the FACIT measurement system. It is a patient-reported questionnaire in which patients rate statements about their financial situation and their sense of control over it. The original version had eleven scored items; the current FACIT version adds a summary item that does not contribute to the total score. Responses are scored into a single number, with lower scores indicating greater financial toxicity.
Two design features explain its adoption. First, it measures the patient's experience of financial burden rather than trying to reconstruct household finances, which makes it feasible in a clinic. Second, it sits within FACIT, the same family of patient-reported outcome measures used for quality of life in oncology trials, so it is familiar to researchers and licensed through the same route. Cancer programs and researchers who want to use COST obtain it through FACIT rather than copying it from a published article.
Other instruments exist, and some health systems screen with a small number of locally written questions instead. What matters operationally is that something is asked, consistently, and that a positive answer routes somewhere.
Who Screens for It
Responsibility varies by program, and in many programs it is genuinely unassigned, which is the core failure mode. Where it is assigned, it usually sits with one of the following.
| Role | Typical contribution |
|---|---|
| Financial counselor or financial navigator | Verifies benefits, estimates out-of-pocket cost, screens for assistance eligibility, and submits applications on the patient's behalf |
| Oncology social worker | Assesses distress including financial distress, connects to charitable and community resources, and addresses the psychosocial consequences |
| Patient navigator | Identifies practical barriers including transportation, lodging, and missed appointments tied to cost, and routes to the right internal resource |
| Nursing and clinic staff | Often the first to hear that a patient did not fill a prescription, and the trigger for referral |
| Pharmacy team | Identifies specialty drug cost sharing at the point of prescribing and initiates manufacturer assistance applications |
Distress screening requirements in cancer program accreditation have made psychosocial screening routine, and financial concerns surface through that channel in many programs even where no dedicated financial screen exists. The role descriptions above overlap in practice; see what oncology social workers do and how patient navigation works for the fuller picture of who owns what.
The Assistance Landscape
Help exists, but it is fragmented across unrelated organizations with different eligibility rules, application processes, and funding cycles. The main categories are these.
Hospital financial counseling and charity care. Nonprofit hospitals are required under Internal Revenue Code section 501(r)(4) to maintain a written financial assistance policy and to publicize it widely, and hospital financial counselors are usually the first stop. They can also identify eligibility for public coverage the patient did not know they qualified for.
Manufacturer patient assistance programs. Drug manufacturers operate programs that provide medication at reduced or no cost to patients meeting income and insurance criteria, and separately operate copay support for commercially insured patients. Eligibility rules differ by program, and federal health care program beneficiaries are generally excluded from manufacturer copay coupons.
Independent charitable copay foundations. Nonprofit foundations offer disease-specific funds that help with cost sharing, including for patients with Medicare. These organizations operate within guidance issued by the HHS Office of Inspector General governing independent charity patient assistance programs. Funds open and close as money is available, so timing matters. Organizations working in this space include the Patient Advocate Foundation, CancerCare, the Leukemia and Lymphoma Society, and the HealthWell Foundation, among others.
Public benefits and coverage programs. Medicaid, marketplace subsidies, Medicare Part D low-income assistance, disability benefits, and state-specific programs. These are often the highest-value option and the slowest to obtain, which is why early screening matters more than late referral.
Professional infrastructure. The Association of Cancer Care Centers maintains a financial advocacy network with training and resources for staff doing this work, and the Association of Oncology Social Work serves the social work side of it. These are useful starting points for programs building a function rather than for individual patients.
Why Cost Conversations Happen Too Late
The recurring pattern in cancer programs is that financial toxicity is discovered at the point of failure, when a patient no-shows, when a prescription goes unfilled, or when a balance goes to collections. By then the assistance options that take weeks to process are less useful.
Three things shift the timing earlier. Screening at or near the start of treatment rather than after a problem appears. A named owner, so that a positive screen has somewhere to go on the same day. And a communication path that works for people who do not answer unknown phone numbers, since much of financial navigation is document collection, application follow-up, and appointment coordination rather than clinical contact. Text-based follow-up is common for exactly that reason, though anything referencing a patient's care is protected health information and has to be handled accordingly.
Frequently Asked Questions
What is financial toxicity in cancer?
It is the harm a patient experiences from the cost of cancer care. The National Cancer Institute defines it as problems related to the cost of medical care, arising from out-of-pocket costs, lost income, and related expenses, which can lead people to delay or skip treatment. It covers both the objective burden and the distress it causes.
What is the COST measure?
COST is the COmprehensive Score for financial Toxicity, a patient-reported questionnaire developed by University of Chicago researchers and published within the FACIT measurement system. It is scored into a single number, with lower scores indicating greater financial toxicity. The original version used eleven scored items and the current FACIT version adds a non-scoring summary item. It is obtained through FACIT rather than reproduced from articles.
Who helps cancer patients with treatment costs?
Usually a hospital financial counselor or financial navigator, an oncology social worker, or a patient navigator, depending on how the cancer program is staffed. Pharmacy teams often initiate manufacturer assistance for specialty drugs. Asking any member of the care team who handles financial assistance is the fastest way to find the right person.
Is financial toxicity only a problem for uninsured patients?
No. Underinsurance is a major driver, meaning coverage that still leaves substantial cost sharing with the patient. Coinsurance on high-cost therapies, deductibles that reset each benefit year, and uncovered indirect costs such as travel and lodging affect insured patients as well, and lost income affects households regardless of coverage.
How is financial toxicity screened for in oncology?
Some programs administer a validated instrument such as COST, some fold financial questions into required distress screening, and some use a short set of locally written questions at intake. The instrument matters less than consistency and having a defined person or team that receives positive screens and acts on them.
What is financial navigation?
Financial navigation is the staffed function that helps patients understand what they will owe, screens them for assistance eligibility, and completes applications for coverage, charity care, manufacturer programs, and charitable funds. It is a distinct role from clinical navigation, though in smaller programs the same person may do both.
Do copay assistance foundations help Medicare patients?
Independent charitable foundations may assist patients with Medicare, operating under guidance from the HHS Office of Inspector General for independent charity patient assistance programs. Manufacturer copay coupons, by contrast, generally exclude beneficiaries of federal health care programs. Eligibility and fund availability change, so check directly with the foundation.
What should someone do if they cannot afford cancer treatment?
Raise it with the care team rather than stopping treatment. Ask to speak with the cancer center's financial counselor or oncology social worker, who can review assistance options, coverage eligibility, and hospital financial assistance policy. This article is general information and not financial or medical advice for any individual situation.
Reaching patients earlier in the process
Most financial navigation work is follow-up: collecting documents, confirming applications, and keeping appointments coordinated while an assistance request is pending. FRANSiS supports that follow-up with two-way texting and an AI Powered Helper that drafts replies for your staff to review and send, with HIPAA compliance supported and a signed BAA included. See FRANSiS for healthcare or contact us to talk through your financial navigation workflow.
